Colorcon Ventures

Colorcon Ventures is the strategic corporate venture capital arm of Colorcon Inc., a global leader in the development, supply, and technical support of specialty products for the pharmaceutical industry. The firm focuses on identifying and investing in innovative solutions that are strategically relevant to Colorcon's core business within the pharmaceutical and nutraceutical sectors. Their investment thesis centers on technologies that enhance patient compliance, support dosage form authentication to combat counterfeiting, and advance drug delivery methods. They also back intelligent systems for digital and personalized medicine, as well as breakthrough innovations in manufacturing and supply chain management.

The venture fund was established in September 2019 with an initial commitment of $50 million. It was launched by Colorcon Inc. to foster external innovation and partner with promising startups in the pharmaceutical and healthcare industries, leveraging Colorcon's extensive industry insight and global reach. The fund is managed in collaboration with Touchdown Ventures, a firm specializing in corporate venture capital. Key individuals involved in approving deals include Martti Hedman, Colorcon's CEO; Dave Graeber, CFO; and Pankaj Rege, Head of Corporate Development. Shahrzad, with deep expertise in drug development, leads Colorcon Ventures.

Colorcon Ventures maintains a diverse portfolio of companies that align with its strategic focus. Notable investments include Syntis Bio, which develops oral therapies for conditions like obesity and diabetes; Phytolon, a biotechnology company creating natural food colorants through precision fermentation; and Vedanta Biosciences, a clinical-stage firm focused on microbial therapeutics. Other portfolio companies include i2O Therapeutics, specializing in oral formulations for therapies traditionally given via injection; Apprentice, which utilizes AI and augmented reality to streamline pharmaceutical manufacturing; Numerion Labs, developing AI/ML solutions for drug discovery; and Remedy, a provider of personalized 3D-printed nutritional gummies.

The team at Colorcon Ventures brings together extensive industry-leading expertise in pharmaceutical excipients, coating systems, and modified release technologies, drawing directly from Colorcon Inc.'s decades of experience. Beyond providing capital, the firm offers strategic support to its portfolio companies through commercial consultation, guidance on sales, and scientific development, aiming to accelerate their growth and ultimately shape the future of pharmaceutical and nutraceutical applications. They are particularly interested in early and mid-stage companies that demonstrate product-market fit and revenue growth, typically providing initial investments ranging from $1 million to $3 million.